Protocol Ledger

NCT05340491 · Phase III · RECRUITING

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Interventional Phase III clinical trial protocol NCT05340491 sponsored by Sun Yat-sen University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-01 Enrollment: 212 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05340491
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)212 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05340491
Protocol FieldVerified Registry Value
NCT IdentifierNCT05340491
Consolidated Lead SponsorSun Yat-sen University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment212 participants (ESTIMATED)
Registered Start Date2022-04-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05340491
Hospital Research SiteLocationSite Profile
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
Sichuan Cancer HospitalChengdu, ChinaOpen Hospital Dossier ->
Zhejiang Cancer HospitalHangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI